TGA rejects monitoring for new oral anticoagulants

There is no evidence to support the need for routine blood monitoring in patients being treated with new oral anticoagulants, the TGA has said. The regulatory body undertook a review following reports that the safety of apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto) could be improved if routine blood monitoring was undertaken. However as manufacturers had ...

Already a member?

Login to keep reading.

© 2022 the limbic